Abdelwahab KS, Ahmed Said ZN. Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol 2016; 22(2): 862-873 [PMID: 26811632 DOI: 10.3748/wjg.v22.i2.862]
Corresponding Author of This Article
Zeinab Nabil Ahmed Said, Professor, Department of Microbiology and Immunology, Faculty of Medicine (for girls), Al-Azhar University, Nasr City, 8, Ossama Ibn Monkez Street, Heliopolis, Cairo 11435, Egypt. znabil58@yahoo.com
Research Domain of This Article
Virology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 14, 2016; 22(2): 862-873 Published online Jan 14, 2016. doi: 10.3748/wjg.v22.i2.862
Status of hepatitis C virus vaccination: Recent update
Kouka Saadeldin Abdelwahab, Zeinab Nabil Ahmed Said
Kouka Saadeldin Abdelwahab, Zeinab Nabil Ahmed Said, Department of Microbiology and Immunology, Faculty of Medicine (for girls), Al-Azhar University, Cairo 11435, Egypt
Author contributions: Abdelwahab KS and Ahmed Said ZN contributed equally to this review.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Zeinab Nabil Ahmed Said, Professor, Department of Microbiology and Immunology, Faculty of Medicine (for girls), Al-Azhar University, Nasr City, 8, Ossama Ibn Monkez Street, Heliopolis, Cairo 11435, Egypt. znabil58@yahoo.com
Telephone: +20-2-1006602418
Received: March 7, 2015 Peer-review started: March 11, 2015 First decision: April 13, 2015 Revised: May 16, 2015 Accepted: September 30, 2015 Article in press: September 30, 2015 Published online: January 14, 2016 Processing time: 305 Days and 13.1 Hours
Core Tip
Core tip: Hepatitis C virus (HCV) is a major global public health problem. Chronic HCV infection affected around 130-150 million of the world’s population. The current treatment is expensive, showed some restrictions and is not efficient for all patients. No licensed vaccine is available for clinical use, however, researches on developing a preventive and therapeutic safe vaccine, are evolving. This review gives an overview of HCV structure, immune response and viral evasion mechanisms. It also evaluates the available preventive and therapeutic vaccines that induce innate, antibody-mediated immune response, cell-mediated immune response and interferon, and highlights the progress in recent HCV vaccination studies either in preclinical or clinical phases.
